Somatotopy of the sensory thalamus: inputs from directional deep brain stimulation in pain patients

Annals of Clinical and Translational Neurology 2024 Jun 11.doi: 10.1002/acn3.52067.  Aurelie Leplus, Petru Isan, Anne Balossier, Sarah Mouffok, Anne Donnet, Theodore Papadopoulo, Michel Lanteri-Minet, Jean Regis, Denys Fontaine Abstract Objective: The sensory ventroposterior (VP) thalamic nuclei display a mediolateral somatotopic organization (respectively head, arm, and leg). We studied

Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study

Neurology 2024 May;102(10):e209349.  doi: 10.1212/WNL.0000000000209349. Epub 2024 Apr 26. Uwe Reuter, Peter J Goadsby, Michel D Ferrari, Gabriel Paiva Da Silva Lima, Subhayan Mondal, Jawed Kalim, Fatima Hasan, Shihua Wen, Michal Arkuszewski, Shaloo Pandhi, Tracy Stites, Michel Lanteri-Minet    Abstract Background and objectives: The LIBERTY study assessed the efficacy and safety of erenumab

“Status trigeminal neuralgia”: Analysis of 39 cases and proposal for diagnostic criteria

Revue Neurologique (Paris) 2024 May 23:S0035-3787(24)00523-X. doi: 10.1016/j.neurol.2024.03.014. Online ahead of print. Z Poullet, S Redon, R Gravier-Dumonceau, A Donnet Abstract Objective: The aim of this descriptive study was to propose diagnostic criteria for acute exacerbation of trigeminal neuralgia (TN) based on the

Triptan use in elderly over 65 years and the risk of hospitalization for serious vascular events

The Journal of Headache and Pain 2024 Apr 26;25(1):68. doi: 10.1186/s10194-024-01770-x. Phuong Thao Tran, Maryse Lapeyre-Mestre, Baricault Berangere, Michel Lanteri-Minet, Aurore Palmaro, Anne Donnet, Joëlle Micallef  Abstract Background: Several studies have focused on the use of triptan and the risk of acute vascular events but the

Discordance between pain specialists and patients on the perception of dependence on pain medication: A multi-center cross-sectional study

Therapie 2024 Apr 12:S0040-5957(24)00043-X doi: 10.1016/j.therap.2024.01.008. Online ahead of print. Anne Roussin, Zénab Cissé, Vanessa Rousseau, Guillaume Roche, Cécile Lestrade, Alexandre Cauchie, Noémie Delage, Anne Donnet, Elise Van Obberghen, Chantal Wood, Maryse Lapeyre-Mestre, Nathalie Cantagrel Abstract Aim: Patients with chronic non-cancer pain are referred to pain centres to improve their pain

Patient Sex in Prescribing CGRP Receptor Antagonists for Migraine

JAMA Neurology JAMA Neurol. Published online February 26, 2024. doi:10.1001/jamaneurol.2023.5835 Michel Lanteri-Minet; Shuu-Jiun Wang; Paolo Martelletti To the Editor In a recent JAMA Neurology Viewpoint,1 Porreca and Dodick raised an important issue by discussing gender differences in outcomes of calcitonin

Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial

The Lancet Neurology 2024 Feb 13:S1474-4422(24)00025-5. doi: 10.1016/S1474-4422(24)00025-5.  Cristina Tassorelli, Krisztián Nagy, Patricia Pozo-Rosich, Michel Lanteri-Minet, Sara Sacco, Tomáš Nežádal, Hua Guo, Rosa De Abreu Ferreira, Giovanna Forero, Joel M Trugman Abstract Background: Atogepant, an oral calcitonin gene-related peptide receptor antagonist, has been approved for the preventive treatment of

Acid-sensing ion channel 3 mediates pain hypersensitivity associated with high-fat diet consumption in mice

PAIN 2024 Feb 1;165(2):470-486. doi: 10.1097/j.pain.0000000000003030. Ahmed Negm, Katharina Stobbe, Selma Ben Fradj, Clara Sanchez, Arnaud Landra-Willm, Margaux Richter, Lucile Fleuriot, Delphine Debayle, Emmanuel Deval, Eric Lingueglia, Carole Rovere, Jacques Noel   Abstract Lipid-rich diet is the major cause of obesity, affecting 13% of the worldwide adult population. Obesity is a